PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25236915-0	2014	Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.	Vilazodone Hydrochloride	68-78	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	13-19	
25236915-2	2014	Vilazodone seems to be metabolized primarily by the cytochrome P-450 (CYP) 3A4 isozyme and non-CYP-mediated pathways; concomitant use of drugs that affect CYP3A4 activity could potentially alter systemic exposure to vilazodone.	Vilazodone Hydrochloride	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	52-78	
25236915-2	2014	Vilazodone seems to be metabolized primarily by the cytochrome P-450 (CYP) 3A4 isozyme and non-CYP-mediated pathways; concomitant use of drugs that affect CYP3A4 activity could potentially alter systemic exposure to vilazodone.	Vilazodone Hydrochloride	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	155-161	
25236915-2	2014	Vilazodone seems to be metabolized primarily by the cytochrome P-450 (CYP) 3A4 isozyme and non-CYP-mediated pathways; concomitant use of drugs that affect CYP3A4 activity could potentially alter systemic exposure to vilazodone.	Vilazodone Hydrochloride	216-226	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	155-161	
25236915-16	2014	IMPLICATIONS: These results suggest that up to a 50% decrease of vilazodone dosage should be considered when it is given in combination with strong CYP3A4 inhibitors; conversely, increasing the vilazodone dosage up to a maximum of 80 mg/d should be considered when it is given in combination with strong CYP3A4 inducers.	Vilazodone Hydrochloride	65-75	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	148-154